News Highlights                    Archives 2018                    Archives 2017                   Archives 2016                   Media Contact                   Media Download Center

February 27, 2020
Appili Therapeutics Reports Financial and Operational Results for Third Quarter Fiscal Year 2020
February 20, 2020
Appili Therapeutics Announces Closing of Public Offering of $10,250,000
February 14, 2020
Appili Therapeutics Announces Upsizing of Previously Announced Equity Offering
February 13, 2020
Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering
February 12, 2020
Appili Therapeutics Announces Overnight Marketed Equity Offering
January 28, 2020
Researchers Present Positive Interim Data on Appili Therapeutics’ ATI-1701 Biodefense Program at 2020 ASM Biothreats
January 7, 2020
Appili Celebrates a Notable 2019 and Looks Ahead to Significant Milestones in 2020
January 27, 2020
Appili Therapeutics Appoints Veteran Biotech Executive Dr. Juergen Froehlich to Its Board of Directors
December 3, 2019
Appili Therapeutics Enters Commercial Agreement With Saptalis Pharmaceuticals for Anticipated Launch of ATI-1501 Antibiotic Candidate in the U.S.
December 2, 2019
Appili Therapeutics Names Dr. Armand Balboni as Chief Executive Officer
November 27, 2019
Appili Therapeutics Reports Financial Results for Second Quarter of Fiscal Year 2020
November 21, 2019
Appili Therapeutics Acquires Clinical Stage Antifungal Program From FUJIFILM Toyama Chemical
November 18, 2019
Researchers Present New Positive Interim Data on Appili Therapeutics’ ATI-1701 Biodefense Program at 2019 Chemical and Biological Defense Science & Technology Conference
September 26, 2019
Appili Therapeutics Announces Voting Results of Annual and Special Meeting of Shareholders
September 16, 2019
Appili Therapeutics Retains BND Projects for Strategic Investor Relations Services
August 21, 2019
Appili Therapeutics Reports Financial Results for First Quarter of Fiscal Year 2020
August 20, 2019
Researchers to Present New Data on Appili Therapeutics Infectious Disease Programs at the 2019 Military Health System Research Symposium
July 3, 2019
Appili Therapeutics Announces FY 2019 Financial Results
June 24, 2019
Appili Therapeutics Common Shares to Begin Trading on June 25, 2019 on the TSXV Under the Stock Symbol “APLI”
July 2, 2019
Appili Therapeutics Signs $3M USD Grant Contract with the United States Department of Defense to Develop Antibiotics that Target Superbugs